Stemlife Berhad
StemLife Berhad is a Malaysian private cord blood bank (founded 2001) that collects, processes, and cryopreserves umbilical cord blood, cord lining, and cord tissue stem cells for expectant parents, operating as a subsidiary of SGX-listed Cordlife Group Limited.
- Company typePrivate
- Founded2001
- HeadquartersKuala Lumpur, Malaysia
- Headcount11–50
- GTM typeB2C
- OfferingServices
What Stemlife Berhad does
StemLife Berhad is a Kuala Lumpur-based private cord blood and cord tissue stem cell bank founded in 2001, operating as a subsidiary of SGX-listed Cordlife Group Limited since 2016. It collects, transports via an in-house logistics fleet, processes, and cryopreserves umbilical cord blood (HSCs), cord lining (CLEpSCs), cord tissue, and peripheral blood stem cells for expectant parents in Malaysia and Brunei, with a cumulative inventory of more than 65,000 cord blood units and credentials including AABB accreditation (since 2018, re-accredited 2020, 2022, 2024), MS ISO 15189, and a PHFS Act 1998 license from the Ministry of Health Malaysia.
The core technology stack rests on the Sepax automated, FDA-cleared, CE-marked cord blood processing system, the patented CellOptima cord lining banking method, ISBT 128 labelling, and a multi-layer (Cobalt) 24/7 cryostorage monitoring system running below -190°C, with cryo-shipper transport validated for 8 days and GPS/CRM tracking. Distribution is anchored by a network of more than 400 doctors across 150+ hospitals and birthing centres in Malaysia and a partnership with Jerudong Park Medical Centre in Brunei. The product mix has expanded beyond core 21-year storage packages (CordMax Plus, CordPlus, Celmax Plus, CelMax) into diagnostic add-ons (Metascreen newborn metabolic screening in 2018, Non-Invasive Prenatal Testing in 2020, Bebegene newborn genetic screening in 2021) and the Moms Up App for expectant mothers.
The business model is predominantly subscription-based with multi-year prepaid contracts (cord blood banking from approximately RM234/month or RM300/year storage plus RM1,000 admin fees), bundled with seven assurance programs (StemAssist, StemShield Plus, StemCourier, Stem21, StemAffirm, CordBlood Network, StemLife Assured). GTM is sales-led through consultant-driven inside sales with strong healthcare-provider channel coverage, event-driven top-of-funnel activity (pregnancy webinars, antenatal classes, World Cord Blood Day), and a Friends & Families referral program. As a wholly consolidated subsidiary of Cordlife Group, StemLife is part of Asia's largest cord blood banking network spanning 11 markets with seven facilities and a group-level net cash position of about SGD 82.7M as of June 2023.
Stemlife Berhad firmographics
Firmographics- Name
- Stemlife Berhad
- Legal name
- StemLife Berhad
- Website
- https://stemlife.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- StemLife Berhad is a Malaysian private cord blood bank (founded 2001) that collects, processes, and cryopreserves umbilical cord blood, cord lining, and cord tissue stem cells for expectant parents, operating as a subsidiary of SGX-listed Cordlife Group Limited.
- Ownership category
- akta.pro rank
Stemlife Berhad industry classification
Industry- Product category
- Cord Blood & Stem Cell Banking
- NAICS
- Blood and Organ Banks (621991)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)
- akta.pro secondary industries
- Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH), Newborn Screening & Genetic Public Health Laboratories (HLAJAIAJ)
Keywords
Where Stemlife Berhad is headquartered
LocationHeadquarters
- HQ city
- Kuala Lumpur
- HQ country
- Malaysia
- HQ region
- Asia
Offices2 records
Markets served
Stemlife Berhad business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure, Supply Chain
Revenue model
- Cord Blood Storage Services: Annual subscription-based storage of cord blood stem cells. Storage fee is RM300 per year. Account opening and transfer incurs RM1,000 admin fee. Services include collection kit, processing, maternal blood testing, viability testing, contamination testing, and 21 years of storage.
- Cord Lining and Wharton’s Jelly Banking: Storage of cord lining containing Mesenchymal Stem Cells (MSCs) and Cord Lining Epithelial Stem Cells (CLEpSCs), plus Wharton’s Jelly. Provided by StemLife Therapeutics Sdn Bhd.
- Package Plans (CordMax Plus, CordPlus, Celmax Plus, CelMax): Comprehensive packages including account establishment, laboratory processing, maternal blood testing, personalised collection kits, viability and contamination testing, enhanced protection programs, StemAffirm, CordBlood Network programs, and 21 years of storage.
- Diagnostic Products: Metascreen (newborn metabolic screening, launched 2018), Non-Invasive Prenatal Testing (NIPT, launched 2020), and Bebegene Newborn Genetic Screening (launched 2021).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Cord Blood Banking - Monthly Plan |
| Subscription | Annual | Annual Storage Fee |
| One time/ perpetual license | Pay-as-you-go | Account Transfer/Opening Fee |
| Subscription | Multi-year contract | CordMax Plus Package |
| Subscription | Multi-year contract | CordPlus, Celmax Plus, CelMax Packages |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels8 records
Stemlife Berhad product offering
Product offeringCore offering
StemLife Berhad collects, processes, and cryopreserves umbilical cord blood, cord lining, and cord tissue stem cells from newborns for long-term family storage. The company also offers peripheral blood stem cell services and a suite of diagnostic products including newborn metabolic screening (Metascreen), non-invasive prenatal testing (NIPT), and newborn genetic screening (Bebegene). Service is delivered through direct enrollment, hospital collection partners, and dedicated logistics across Malaysia and the broader Cordlife Group network in Asia.
Product overview
StemLife Berhad operates as a comprehensive stem cell banking service provider offering multiple tiers of cord blood, cord lining, and cord tissue banking packages (CordMax Plus, CordPlus, Celmax Plus, CelMax). The company has expanded into diagnostic products including Metascreen (newborn metabolic screening, 2018), NIPT (non-invasive prenatal testing, 2020), and Bebegene (newborn genetic screening, 2021). Additional services include peripheral blood stem cell collection, a Therapy Centre for patient assistance, and the Moms Up App for expectant parents. The portfolio is supported by proprietary technologies including CellOptima for cord lining processing and Sepax automated processing systems, all backed by AABB accreditation and MS ISO 15189 certification.
Differentiator
Problem solved
Functional benefit
Brands
- CordMax Plus: Premium cord blood banking package including cord blood, cord lining, and Wharton's Jelly storage with HSC, CLEpSC, and MSC preservation
- CordPlus
- Celmax Plus
- CelMax
- StemAssist
- StemLife Assured
- StemShield Plus
- StemCourier
- Stem21
- StemAffirm
- CordBlood Network
- Metascreen
- Bebegene
- Moms Up App
Products and services
- Cord Blood Banking Collection, processing, testing, and 21-year cryopreservation of umbilical cord blood containing Haematopoietic Stem Cells (HSCs) for potential treatment of over 80 diseases including leukaemia, lymphoma, and other blood disorders; targeted at expectant parents and families.
- Cord Lining Banking
Quantifiable outcome
- 100% physician acceptance rate for cord blood units released
- +4 more outcomes
Companies that use Stemlife Berhad
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
Stemlife Berhad technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature6 records
Stemlife Berhad partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered minor and core.
- AMILIminorCordlife and AMILI partnered to launch the first-ever gut microbiome banking service in Southeast Asia.
- Jerudong Park Medical Centre (JPMC)minorStemLife collaborates with JPMC to offer cord blood banking services to the Brunei market. StemLife opened a Stem Cell Banking Resource Centre at JPMC in 2020.
- StemLife Logistics Sdn BhdcoreLaunched in 2007 to provide end-to-end comprehensive logistics service with a fleet of acquired logistics vehicles for specimen transport.
- ThaiStemLifecoreIncorporated in 2005, ThaiStemLife is Thailand's largest cord blood bank in which StemLife has a direct stake. Part of the group's regional expansion strategy.
- StemLife Therapeutics Sdn. Bhd.coreLaunched in May 2005 for Peripheral Blood Stem Cells (PBSC) service. Also provides cord lining and Wharton's Jelly banking services.
- Asia Pacific Cord Blood Bank Consortium (APCBBC)minorCo-founded in 2003 with cord blood banks from Taiwan, Hong Kong, South Korea, Singapore, Australia, Japan, Thailand, Vietnam and Egypt to promote collaboration in cord blood banking industry.
- Malaysia Association for Cell Therapy (MACT)minorStemLife is a member of MACT, the Malaysia Association for Cell Therapy.
Scale indicators10 records
Recent moves11 records
Expansion highlights6 records
Stemlife Berhad competitors and assessment
Company assessmentDirect peers
- Cordlife Group Limited: Parent company of StemLife and operator of Asia's largest cord blood bank network with 7 facilities in 6 markets. Direct comparable on storage technology, AABB accreditation, and pediatric diagnostic services.
- HealthBaby Hong Kong: Sister company within the Cordlife Group network operating cord blood and cord tissue banking in Hong Kong. Directly comparable as a sister subsidiary with the same group governance and technology stack.
- StemCord: Singapore-based private cord blood bank offering cord blood, cord lining, and cord tissue storage. Direct competitor in Southeast Asia with overlapping prenatal and newborn services.
- CryoCord: Malaysian private cord blood and tissue bank offering similar AABB-compliant storage services. Direct domestic competitor within StemLife's home market with comparable hospital partnerships.
- Cellsafe International: Was a Malaysian private cord blood bank operating in the same market before ceasing operations in 2023. Historical direct peer that competed on the same product set and customer base.
- Smart Cells International: UK-based private stem cell bank offering cord blood and cord tissue storage globally. Comparable subscription-based storage model with international footprint and similar pricing tiers.
- BioCordcell Bangladesh: Sister entity within the Cordlife Group network serving Bangladesh. Directly comparable in service offerings and quality framework as part of the same regional operations.
Broad incumbents
- Cryo-Cell International: US-listed pioneer in private cord blood banking offering cord blood and menstrual stem cell banking. Established global incumbent with similar business model and 30+ years of operating history.
- ViaCord: US-based private cord blood bank owned by Revvity (formerly PerkinElmer). Comparable cord blood and cord tissue storage products targeting expectant parents with a more mature North American market footprint.
- CBR (Cord Blood Registry): Largest US cord blood bank now part of CooperSurgical. Comparable service portfolio and parent-focused GTM model with hospital partnerships and OB/GYN distribution.
Market position
Strengths5 records
Weaknesses3 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Stemlife Berhad social profiles
Digital presenceStemlife Berhad compliance and trust
Trust signalCompliance5 records
Stemlife Berhad financial estimates
Financial estimateRevenue estimate
Valuation estimate
Stemlife Berhad leadership team
Management profileNumber of profiles
Profiles1 record
Stemlife Berhad subsidiaries and ownership
Company hierarchySubsidiaries3 records
Stemlife Berhad funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Stemlife Berhad M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Stemlife Berhad
What does Stemlife Berhad do?
StemLife Berhad collects, processes, and cryopreserves umbilical cord blood, cord lining, and cord tissue stem cells from newborns for long-term family storage. The company also offers peripheral blood stem cell services and a suite of diagnostic products including newborn metabolic screening (Metascreen), non-invasive prenatal testing (NIPT), and newborn genetic screening (Bebegene). Service is delivered through direct enrollment, hospital collection partners, and dedicated logistics across Malaysia and the broader Cordlife Group network in Asia.
Is Stemlife Berhad a public or private company?
Stemlife Berhad is a private company. It is classified as corporate owned and is currently operating.
When was Stemlife Berhad founded?
Stemlife Berhad was founded in 2001. It employs 11 to 50 people.
Where is Stemlife Berhad based?
Stemlife Berhad is headquartered in Kuala Lumpur, Malaysia, in the Asia region.
How does Stemlife Berhad make money?
Four revenue lines are on record. Cord Blood Storage Services are the primary driver. The others are cord Lining and Wharton’s Jelly Banking, package Plans (CordMax Plus, CordPlus, Celmax Plus, CelMax) and diagnostic Products.
Who are Stemlife Berhad's main competitors?
Direct peers on record are Cordlife Group Limited, HealthBaby Hong Kong, StemCord, CryoCord, Cellsafe International, Smart Cells International and BioCordcell Bangladesh. Broad incumbents are Cryo-Cell International, ViaCord and CBR (Cord Blood Registry).
Does Stemlife Berhad have an API?
No public API is recorded for Stemlife Berhad.
What industry is Stemlife Berhad in?
Stemlife Berhad's product category is Cord Blood & Stem Cell Banking. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue), with a secondary code of HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening). Its NAICS code is 621991 and its SIC code is 2836.